SLC5A2 and metabolic dysfunction-associated steatohepatitis: SGLT2 inhibitors markedly reduce steatosis and normalize the liver tissue composition (Omori et al., 2019[63]) and thus can serve as promising therapeutic agents for patients with NASH.